Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.

about

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.

Item

http://www.wikidata.org/entity/Q48215818

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Preclinical evaluation of anti ...... epatocellular carcinoma cells.

@en

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238

@nl

type

Item

label

Preclinical evaluation of anti ...... epatocellular carcinoma cells.

@en

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238

@nl

prefLabel

Preclinical evaluation of anti ...... epatocellular carcinoma cells.

@en

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238

@nl

P1476

Preclinical evaluation of anti ...... epatocellular carcinoma cells.

@en

P2093

Antonella Cusimano

http://www.w3.org/2001/XMLSchema#string

Antonina Azzolina

http://www.w3.org/2001/XMLSchema#string

Caterina Di Sano

http://www.w3.org/2001/XMLSchema#string

Giovanni Cassata

http://www.w3.org/2001/XMLSchema#string

Giuseppa Augello

http://www.w3.org/2001/XMLSchema#string

Maria Rita Emma

http://www.w3.org/2001/XMLSchema#string

Martina Modica

http://www.w3.org/2001/XMLSchema#string

P2860

Spotlight on ixazomib: potential in the treatment of multiple myeloma

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.

Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.

The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells

Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.

Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41419-017-0195-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Puleio

Giuseppe Montalto

Melchiorre Cervello

P577

2018-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29348495

http://www.w3.org/2001/XMLSchema#string

P932

5833482

http://www.w3.org/2001/XMLSchema#string